Condition
Hemophilia A or B
Total Trials
4
Recruiting
1
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 3 (1)
Trial Status
Completed2
Active Not Recruiting1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07545395Phase 3RecruitingPrimary
Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
NCT07161687Active Not RecruitingPrimary
A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.
NCT03363321Phase 2CompletedPrimary
PF-06741086 Long-term Treatment in Severe Hemophilia
NCT02974855Phase 2CompletedPrimary
PF-06741086 Multiple Dose Study in Severe Hemophilia
Showing all 4 trials